Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Jul 12:13:934156.
doi: 10.3389/fphar.2022.934156. eCollection 2022.

Nanostructured Lipid Carrier-Based Delivery of Pioglitazone for Treatment of Type 2 Diabetes

Umair Ilyas  1 , Muhammad Asif  1 , Minglian Wang  2 , Reem Altaf  3 , Hajra Zafar  4 , Mirza Muhammad Faran Ashraf Baig  5 , Ana Cláudia Paiva-Santos  6   7 , Muhammad Abbas  1
Affiliations

Nanostructured Lipid Carrier-Based Delivery of Pioglitazone for Treatment of Type 2 Diabetes

Umair Ilyas et al. Front Pharmacol. .

Abstract

Pioglitazone (PGZ) is utilized as a therapeutic agent in the management of (type 2) diabetes to control blood glucose levels. The existing research work was intended to make and optimize PGZ-containing NLCs (nanostructured lipid carriers). The fabricated nanostructured lipid carrier preparation was optimized by using different concentrations of the surfactants (Tween 80 and Span 80) and solid lipid (Compritol® 888 ATO) and liquid lipid (Labrasol®) while keeping the concentration of drug (PGZ), and co-surfactants (poloxamer 188) the same. The optimized NLC formulation (PGZ-NLCs) was further assessed for physical and chemical characterization, in vitro PGZ release, and stability studies. The optimized PGZ-NLCs have shown an average diameter of 150.4 nm, EE of 92.53%, PDI value of 0.076, and zeta-potential of -29.1 mV, correspondingly. The DSC thermal analysis and XRD diffractograms had not presented the spectrum of PGZ, confirming the comprehensive encapsulation of PGZ in the lipid core. PGZ-NLCs showed significantly extended release (51% in 24 h) compared to the unformulated PGZ. Our study findings confirmed that PGZ-NLCs can be a promising drug delivery system for the treatment of type 2 diabetes.

Keywords: NLCs; diabetes; nanoparticles; pioglitazone; poor aqueous solubility.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

FIGURE 1
FIGURE 1
Optimized PGZ-NLCs. (A) Particle size distribution; (B) zeta potential.
FIGURE 2
FIGURE 2
SEM image of optimized PGZ-NLCs.
FIGURE 3
FIGURE 3
FTIR spectra of (A) PGZ, (B) Compritol 888 ATO, (C) poloxamer 188, and (D) optimized PGZ-NLCs.
FIGURE 4
FIGURE 4
Powder X-ray diffraction pattern of (A) PGZ, (B) Compritol 888 ATO, (C) poloxamer 188, and (D) optimized PGZ-NLCs.
FIGURE 5
FIGURE 5
DSC thermogram of (A) PGZ, (B) Compritol 888 ATO, (C) poloxamer 188, and (D) optimized PGZ-NLCs.
FIGURE 6
FIGURE 6
(A) Comparative profiles of in vitro release of unformulated PGZ and PGZ-NLCs in simulated gastric fluid. (B) Comparative profiles of in vitro release of unformulated PGZ and PGZ-NLCs in simulated intestinal fluid.
FIGURE 7
FIGURE 7
Stability study of PGZ-NLCs (A) at 25°C and (B) 40°C.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. AmeeduzzafarEl-Bagory I., El-Bagory I., Alruwaili N. K., Elkomy M. H., Ahmad J., Afzal M., et al. (2019). Development of Novel Dapagliflozin Loaded Solid Self-Nanoemulsifying Oral Delivery System: Physiochemical Characterization and In Vivo Antidiabetic Activity. J. Drug Deliv. Sci. Technol. 54, 101279. 10.1016/j.jddst.2019.101279 - DOI
    1. Bhosale U., Galgatte U., Chaudhari P. (2016). Development of Pioglitazone Hydrochloride Lipospheres by Melt Dispersion Technique: Optimization and Evaluation. J. App Pharm. Sci. 6 (01), 107–117. 10.7324/japs.2016.600118 - DOI
    1. Casula L., Sinico C., Valenti D., Pini E., Pireddu R., Schlich M., et al. (2021). Delivery of Beclomethasone Dipropionate Nanosuspensions with an Electronic Cigarette. Int. J. Pharm. 596, 120293. 10.1016/j.ijpharm.2021.120293 - DOI - PubMed
    1. Eckland D., Danhof M. (2000). Clinical Pharmacokinetics of Pioglitazone. Exp. Clin. Endocrinol. diabetes 108 (Suppl. 2), 234–242. 10.1055/s-2000-8525 - DOI
    1. Elbary A. A., Kassem M. A., Abou Samra M. M., Khalil R. M. (2008). Formulation and Hypoglycemic Activity of Pioglitazone-Cyclodextrin Inclusion Complexes. Drug Discov. Ther. 2 (2), 94–107. - PubMed

LinkOut - more resources

  NODES
INTERN 2
twitter 2